Document Detail

Lymphangiogenesis and prognostic significance of vascular endothelial growth factor C in gastro-oesophageal junction adenocarcinoma.
MedLine Citation:
PMID:  23317352     Owner:  NLM     Status:  MEDLINE    
Vascular endothelial growth factor C (VEGF-C) is a crucial regulator of the development of lymphatic vessels and is involved in the lymph node metastasis of cancer. The levels of VEGF-C expression and lymphatic vessel density (LVD) in 128 gastro-oesophageal junction adenocarcinoma (GEJA) tissues were examined by immunohistochemistry and analysed for their association with clinicopathological features and disease-free survival. We found that 75.0% of tumour samples displayed strong immunoreactivity to VEGF-C. The levels of VEGF-C expression in the tumour tissues were associated with the stages of the clinical tumours and the lymph node metastasis status, but not with the age, gender and the size and type of tumours in the cohort. Similarly, LVD, as evaluated by anti-D2-40 staining, was also associated with the clinical stages of GEJA. The values of LVD were positively correlated with the levels of VEGF-C expression in these samples (r = 0.3760, P = 0.0001). High levels of VEGF-C expression and high values of LVD were associated with shorter periods of disease-free survival (DFS) in patients with GEJA (P < 0.001). In addition, GEJA at N1 and N2 stages, at T4 stage, chemotherapy after surgery, high levels of VEGF-C expression and lower marginal resection were independent factors for the prognosis of DFS in patients with GEJA. Our data indicate that VEGF-C may promote the lymphangiogenesis and lymphatic metastasis of GEJA and that VEGF-C may be a valuable biomarker for the diagnosis of lymphatic metastasis and a prognostic factor of the survival of patients with GEJA.
Liang-Xi Xie; Tian-Tian Zhai; Li-Ping Yang; Eleanor Yang; Xiao-Hui Zhang; Jiong-Yu Chen; Hao Zhang
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  International journal of experimental pathology     Volume:  94     ISSN:  1365-2613     ISO Abbreviation:  Int J Exp Pathol     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-15     Completed Date:  2013-03-05     Revised Date:  2014-02-04    
Medline Journal Info:
Nlm Unique ID:  9014042     Medline TA:  Int J Exp Pathol     Country:  England    
Other Details:
Languages:  eng     Pagination:  39-46     Citation Subset:  IM    
Copyright Information:
© 2012 The Authors. International Journal of Experimental Pathology © 2012 International Journal of Experimental Pathology.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adenocarcinoma / chemistry*,  mortality,  pathology,  therapy
Aged, 80 and over
Disease-Free Survival
Esophageal Neoplasms / chemistry*,  mortality,  pathology,  therapy
Esophagogastric Junction / chemistry*,  pathology
Kaplan-Meier Estimate
Lymphatic Metastasis
Middle Aged
Multivariate Analysis
Neoplasm Staging
Proportional Hazards Models
Stomach Neoplasms / chemistry*,  mortality,  pathology,  therapy
Time Factors
Treatment Outcome
Tumor Markers, Biological / analysis*
Vascular Endothelial Growth Factor C / analysis*
Reg. No./Substance:
0/Tumor Markers, Biological; 0/VEGFC protein, human; 0/Vascular Endothelial Growth Factor C

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Knowledge and confidence of Australian emergency department clinicians in managing patients with men...
Next Document:  Changes in liver gluconeogenesis during the development of Walker-256 tumour in rats.